ADMA

BIVIGAM®

Primary humoral immunodeficiency (PI)

Stage (next event)

Next Event

Expected Date

Approved

Quarterly Sales

March 05, 2021 (Est)

Achieved Fourth Quarter 2020 Preliminary Unaudited Total Revenues of $13.9 Million, the Highest Revenue Quarter for the Company Since Inception

Catalyst Info & Data Links

MORE INFORATION:

Label
Achieved Fourth Quarter 2020 Preliminary Unaudited Total Revenues of $13.9 Million, the Highest Revenue Quarter for the Company Since Inception

DRUG HISTORY:

Q3 2020 sales $28.3 Million
2020 Revenue Guidance: N/A
01-19-2021 Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook
07-08-2019 ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
01-07-2019 ADMA Biologics Submits Response and Provides Supplemental Information to FDA for BIVIGAM® Complete Response Letter

Mechanism of Action

BIVIGAM is a replacement therapy in patients with primary humoral immunodeficiency (PI) (e.g. agammaglobulinaemia, hypogammaglobulinaemia, CVID, SCID). The broad spectrum of neutralizing IgG antibodies against bacterial and viral pathogens and their toxins helps to avoid recurrent serious opportunistic infections. IgG antibodies are opsonins that increase phagocytosis and elimination of pathogens from the circulation. The mechanism of action has not been fully elucidated in PI.

ADMA, BIVIGAM®, primary humoral immunodeficiency (PI) (e.g. agammaglobulinaemia, hypogammaglobulinaemia, CVID, SCID), IgG antibodies

Prior Data (click to view full image)